MIST - Milestone Pharmaceuticals Inc.
IEX Last Trade
1.92
0.030 1.563%
Share volume: 11,071
Last Updated: Thu 26 Dec 2024 08:25:43 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$1.89
0.03
1.59%
Fundamental analysis
25%
Profitability
25%
Dept financing
16%
Liquidity
75%
Performance
15%
Performance
5 Days
0 0%
1 Month
0 0%
3 Months
22.52%
6 Months
38.06%
1 Year
-7.04%
2 Year
-51.06%
Key data
Stock price
$1.92
DAY RANGE
$1.85 - $1.91
52 WEEK RANGE
$1.34 - $2.40
52 WEEK CHANGE
$4.52
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Joseph G. Oliveto
Region: US
Website: milestonepharma.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: milestonepharma.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Milestone Pharmaceuticals Inc. focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada.
Recent news